su011248
Gastroenteropancreatic Neuroendocrine Tumor Disease
RayzeBio, Inc.Phase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Gastroenteropancreatic Neuroendocrine Tumor Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | B |
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →